<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03663686</url>
  </required_header>
  <id_info>
    <org_study_id>HEC46877-P-01</org_study_id>
    <nct_id>NCT03663686</nct_id>
  </id_info>
  <brief_title>The Safety, Tolerability and Pharmacokinetic Study of Litapiprant Tablets in Healthy Male and Female Subjects</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Single-center Study to Assess the Safety, Tolerability and Pharmacokinetic of Litapiprant Tablets in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunshine Lake Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunshine Lake Pharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Safety, Tolerability and Pharmacokinetic Study of Asthma Treatment Drug Litapiprant
      Tablets in Healthy Male and Female subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a Randomized，Double-blind, Placebo-controlled, Single Ascending Dose, Single-center
      Study to Assess the Safety, Tolerability and Pharmacokinetic of Litapiprant Tablets in
      Healthy Male and Female subjects. A total of 60 healthy subjects were divided into 7 groups.
      Group 1 consist of 4 subjects, 3 subjects will receive Litapiprant Tablets and 1 subject will
      receive placebo.Group 2,3,5,6 consist of 8 subjects respectively, in each group, 6 subjects
      will receive Litapiprant Tablets and 2 subjects will receive placebo.Group 4,7 consist of 12
      subjects respectively, in each group, 10 subjects will receive Litapiprant Tablets and 2
      subjects will receive placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 25, 2018</start_date>
  <completion_date type="Actual">January 30, 2019</completion_date>
  <primary_completion_date type="Actual">January 30, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Baseline to day 8~10</time_frame>
    <description>To assess the safety and tolerability after a single dose of Litapiprant Tablets</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-∞</measure>
    <time_frame>Prior to dosing（0 hour）and 0.25 hour、0.5 hour、1 hour、1.5 hours、2 hours、3 hours、4 hours、6 hours、8 hours、10 hours、12 hours、24 hours、36 hours、48 hours、72 hours、96 hours after dosing</time_frame>
    <description>area under the concentration versus time curve (AUC) from time zero to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>Prior to dosing（0 hour）and 0.25 hour、0.5 hour、1 hour、1.5 hours、2 hours、3 hours、4 hours、6 hours、8 hours、10 hours、12 hours、24 hours、36 hours、48 hours、72 hours、96 hours after dosing</time_frame>
    <description>AUC from time zero to the time of the last quantifiable concentration time zero to the time of the last quantifiable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Prior to dosing（0 hour）and 0.25 hour、0.5 hour、1 hour、1.5 hours、2 hours、3 hours、4 hours、6 hours、8 hours、10 hours、12 hours、24 hours、36 hours、48 hours、72 hours、96 hours after dosing</time_frame>
    <description>maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax</measure>
    <time_frame>Prior to dosing（0 hour）and 0.25 hour、0.5 hour、1 hour、1.5 hours、2 hours、3 hours、4 hours、6 hours、8 hours、10 hours、12 hours、24 hours、36 hours、48 hours、72 hours、96 hours after dosing</time_frame>
    <description>time of the maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t½</measure>
    <time_frame>Prior to dosing（0 hour）and 0.25 hour、0.5 hour、1 hour、1.5 hours、2 hours、3 hours、4 hours、6 hours、8 hours、10 hours、12 hours、24 hours、36 hours、48 hours、72 hours、96 hours after dosing</time_frame>
    <description>apparent terminal elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F</measure>
    <time_frame>Prior to dosing（0 hour）and 0.25 hour、0.5 hour、1 hour、1.5 hours、2 hours、3 hours、4 hours、6 hours、8 hours、10 hours、12 hours、24 hours、36 hours、48 hours、72 hours、96 hours after dosing</time_frame>
    <description>apparent volume of distribution</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>25mg single doses</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intervention Drug: 25mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50mg single doses</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intervention Drug: 50mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100mg single doses</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intervention Drug: 100mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200mg single doses</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intervention Drug: 200mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>400mg single doses</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intervention Drug: 400mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>600mg single doses</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intervention Drug: 600mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>800mg single doses</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intervention Drug: 800mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Litapiprant Tablet</intervention_name>
    <description>Small molecules inhibitors of the chemoattractant receptor homologous molecule expressed on Th2 cells</description>
    <arm_group_label>100mg single doses</arm_group_label>
    <arm_group_label>200mg single doses</arm_group_label>
    <arm_group_label>25mg single doses</arm_group_label>
    <arm_group_label>400mg single doses</arm_group_label>
    <arm_group_label>50mg single doses</arm_group_label>
    <arm_group_label>600mg single doses</arm_group_label>
    <arm_group_label>800mg single doses</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, overall healthy subjects，female VS male 1:1 ratio;

          -  Between 18 and 45 years of age, inclusive, similar ages;

          -  Body weight should be≥50 kg; Body Mass Index (BMI) is between 19.0 and 28.0 kg/m2,
             inclusive;

          -  Able to comprehend and sign the ICF voluntarily prior to initiate the study;

          -  Able to communicate well with the investigator and complete the study according to the
             protocol.

        Exclusion Criteria:

          -  Pregnant or nursing female, or plan for pregnancy within 6 months;

          -  A clinically significant abnormal finding on the physical exam, medical history,
             electrocardiogram (ECG), or clinical laboratory results at screening;

          -  Has a positive test for hepatitis B surface antigen, hepatitis C antibody, syphilis
             antibody， or HIV antibody . A clinically significant abnormal finding on HBV-DNA test
             ;

          -  Sitting systolic blood pressure (SBP) &lt;90mmHg or &gt;140mmHg, and/or sitting diastolic
             blood pressure (DBP) &lt;60mmHg or &gt;90mmHg at screening;

          -  With the history of using any drug which will inhibit or induce liver metabolize drug
             and/or will infect gastric acid within 1 month before randomization;

          -  Receipt of any medication including over the counter preparations and vitamins within
             14 days of the first study day;

          -  History of cardiovascular, immune system, Severe digestive system, Circulatory system,
             respiratory system, urinary system , nervous system,tumor diseases;

          -  Suffering from blood diseases such as coagulopathy;

          -  Patients with a history of mental illness or active mental illness;

          -  Have undergone major surgery within 6 months before enrollment;

          -  A history of gastrointestinal, liver ,kidney diseases likely to influence drug
             absorption within 6 months before enrollment;

          -  Drug or alcohol abuse;

          -  History of drug abuse and drug use within 1 year prior to the study;

          -  Habitual consumption of grapefruit juice, tea, coffee and/or caffeinated beverages,
             which cannot be withdrawn during the trial;

          -  The average daily smoking volume is &gt;5 within 3 months prior to the study;

          -  A history of hypersensitivity and/or idiosyncrasy to any of the test compounds or
             related drugs or excipients employed in this study;

          -  Participation in a clinical study within 3 months of the first dose of study drug;

          -  Donation of blood within 3 months of the first dose of study drug or have a plan to
             donate blood;

          -  Cannot be tolerant to oral drugs;

          -  Poor peripheral venous access conditions;

          -  The investigator believes that it should not be included;

          -  Additional exclusion criteria apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xinghe Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Shijitan Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing shijitan hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100038</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>September 2, 2018</study_first_submitted>
  <study_first_submitted_qc>September 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2018</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

